Beam Therapeutics Inc (BEAM)

May 29, 2025, 4:01 PM EDT - 4 days ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 14, 2025, 9:30 AM EDT - 20 days ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 13, 2025, 7:00 AM EDT - 21 days ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:01 PM EDT - 21 days ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 6, 2025, 7:00 AM EDT - 4 weeks ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 5, 2025, 7:00 AM EDT - 2 months ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Mar 31, 2025, 2:25 PM EDT - 2 months ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Mar 27, 2025, 4:01 PM EDT - 2 months ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 21, 2025, 1:13 PM EDT - 2 months ago

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Mar 10, 2025, 9:07 AM EDT - 3 months ago

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Mar 10, 2025, 6:01 AM EDT - 3 months ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:00 AM EDT - 3 months ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Feb 25, 2025, 7:00 AM EST - 3 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 24, 2025, 7:00 AM EST - 3 months ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Jan 30, 2025, 7:00 AM EST - 4 months ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:00 AM EST - 4 months ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 13, 2025, 7:00 AM EST - 5 months ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Dec 8, 2024, 1:45 PM EST - 6 months ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 6 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 6, 2024, 7:00 AM EST - 6 months ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 4, 2024, 7:00 AM EST - 6 months ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Nov 12, 2024, 4:01 PM EST - 7 months ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 7, 2024, 2:25 PM EST - 7 months ago

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 5, 2024, 11:54 AM EST - 7 months ago

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 6:30 AM EST - 7 months ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Oct 29, 2024, 6:30 AM EDT - 7 months ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Aug 6, 2024, 6:30 AM EDT - 10 months ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Jul 15, 2024, 6:30 AM EDT - 11 months ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Jun 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 14, 2024, 3:00 AM EDT - 1 year ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

May 30, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

May 14, 2024, 4:00 PM EDT - 1 year ago

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

May 8, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

May 7, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

Mar 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Feb 28, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences

Feb 27, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones

Feb 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 8, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones

Jan 2, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 14, 2023, 6:30 AM EST - 1 year ago

Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

Nov 30, 2023, 4:36 AM EST - 1 year ago

CRISPR Gene Editing: Beam Therapeutics

Nov 10, 2023, 4:50 PM EST - 1 year ago

Beam Therapeutics: Sale Of Rights To Verve's In-Vivo Candidates An Odd Decision

Nov 8, 2023, 6:30 AM EST - 1 year ago

Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference

Nov 8, 2023, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results

Oct 31, 2023, 6:00 AM EDT - 1 year ago

Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease

Oct 25, 2023, 6:30 AM EDT - 1 year ago

Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT

Oct 22, 2023, 6:39 AM EDT - 1 year ago

Beam: Opportunity Based On SCD Data Readout In 2024

Oct 19, 2023, 9:06 AM EDT - 1 year ago

Beam Therapeutics to cut 20% of workforce as part of restructuring plan

Oct 19, 2023, 8:56 AM EDT - 1 year ago

Beam Therapeutics to reduce staff by 20% as it seeks to extend cash runway into 2026